Nyrada Inc. (NYR.AX)

0.0820 -0.0090 (-9.89%) At close: 03:20PM AEST

Nyrada Inc.

828 Pacific Highway
Suite 2 Level 3
Gordon, NSW 2072
Australia
61 2 9498 3390
https://www.nyrada.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Bonnar	Chief Executive Officer	348.94k	N/A	N/A
Mr. Cameron Jones C.A.	Chief Financial Officer	N/A	N/A	N/A
Mr. Benjamin Evison Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Dimitri Burshtein	Investor Relations Manager	N/A	N/A	N/A
Mr. Mark Waring B.Sc., P.M.P.	Senior Vice President of US Operations	N/A	N/A	N/A
Mr. David James Franks BEc, C.A., F Fin, J.P.	Company Secretary	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurodegenerative diseases. Its products in the drug development stage includes PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce the disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.

Corporate governance

Nyrada Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.